Publications

Journal Article
Research Support, U.S. Gov't, P.H.S.
Ppublish 198 citations
Electronic publication date
February 18, 2004

View on Pubmed.gov 14730625 | View on doi.org 10.1002/art.114...

Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice.

Search for publications in this journal Arthritis Rheum - 50(1):265-76

Abstract

OBJECTIVE

To investigate the mechanisms whereby tumor necrosis factor alpha (TNFalpha) increases osteoclastogenesis in vivo.

METHODS

TNFalpha-transgenic (TNF-Tg) and wild-type mice injected with TNFalpha were studied. In vitro osteoclastogenesis assays, monocyte colony-forming assays, and fluorescence-activated cell sorting were performed using splenocytes, peripheral blood mononuclear cells (PBMCs), and bone marrow cells to quantify and characterize osteoclast precursors (OCPs). Etanercept, a TNFalpha antagonist, was used to block TNFalpha activity in vivo. The effects of TNFalpha on proliferation, apoptosis, and differentiation of OCPs were assessed using 5-bromo-2'-deoxyuridine labeling, annexin V staining, and reverse transcriptase-polymerase chain reaction.

RESULTS

OCP numbers were increased 4-7-fold in PBMCs and spleen, but not in bone marrow of TNF-Tg mice. The OCPs in spleen were in the CD11b(high) population and contained both c-Fms- and c-Fms+ cells. The increased number of OCPs correlated with the initiation of detectable TNFalpha in serum and the onset of inflammatory arthritis in TNF-Tg mice. Etanercept eliminated the increase in peripheral OCPs. TNFalpha did not affect proliferation, survival, or differentiation of CD11b(high) splenocytes in vivo or in vitro, but caused a rapid increase in CD11b+ cells in blood within 4 hours of a single injection and an accumulation of CD11b(high) OCPs in spleen after 3 days of multiple injections.

CONCLUSION

Systemic TNFalpha induces a marked increase in circulating OCPs that is reversible by anti-TNF therapy and may result from their mobilization from bone marrow. Our findings provide a new mechanism whereby TNFalpha stimulates osteoclastogenesis in patients with inflammatory arthritis, suggesting that CD11b+ PBMCs could be used to evaluate a patient's potential for erosive disease and the efficacy of anti-TNF therapy.

References

No references provided.

Cited by 198 citations (total)

Journal Article Research Support, N.I.H., Extramural

TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood.

Electronic publication date September 24, 2008

Search for publications in this journal Arthritis Res Ther

Qian Zhang [...] Lianping Xing et al.

INTRODUCTION

The objective of the present study was to investigate the role of the stromal cell-derived factor 1 (SDF-1)/CXCR4 axis in...

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts.

Electronic publication date June 11, 2009

Search for publications in this journal J Cell Biochem

Kosuke Mizutani [...] Kenneth J Pienta et al.

Bone is the preferred site of prostate cancer metastasis, contributing to the morbidity and mortality of this disease. A key...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances